Lexicon to lay off 50% of field force as it prioritizes heart failure drug, potential US diabetes launch

[cafead]

via Despite winning an FDA approval in 2023 and gaining clarity in May on the regulatory path forward for its Type 1 diabetes prospect sotagliflozin, Lexicon Pharmaceuticals hasn’t had an easy go of it in recent years.

article source